Full-Time
Develops cortisol modulators for medical conditions
$140k - $155k/yr
Senior
Orlando, FL, USA
Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing stress, metabolism, and immune functions. Their main product, Korlym, is the first FDA-approved treatment for Cushing's syndrome, a condition caused by excessive cortisol. Corcept has created over 1,000 selective cortisol modulators through extensive research and development. Unlike many competitors, Corcept not only sells its approved drug but also invests in educational resources for healthcare professionals and patients to improve understanding and care for cortisol-related conditions. The company's goal is to expand its treatment options for patients suffering from serious medical conditions linked to cortisol imbalances.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Menlo Park, California
Founded
1998
Help us improve and share your feedback! Did you find this helpful?
Remote Work Options
Flexible Work Hours
CORCEPT to present late-breaking data from pivotal Phase 3 ROSELLA trial of Relacorilant in platinum-resistant Ovarian Cancer at ASCO 2025.
NEW YORK, NY / ACCESS Newswire / March 18, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Corcept Therapeutics Incorporated ("Corcept Therapeutics Incorporated") (NASDAQ:CORT) concerning possible violations of federal securities laws.
Corcept Therapeutics (NASDAQ: CORT) has launched the MOMENTUM clinical trial to investigate the prevalence of endogenous hypercortisolism (Cushing's syndrome) in patients with resistant hypertension.
The investigation concerns whether Corcept and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Corcept Therapeutics Incorporated (CORT): the Best Performing Pharma stock So Far in 2025.